The Zyprexa Papers

On December 17, 2006, a significant revelation unfolded as The New York Times reported on newly uncovered documents linking the pharmaceutical company behind Zyprexa, an antipsychotic drug, to serious ethical concerns. This set of documents shed light on the company's practices and the potential dangers of their drug, particularly relating to its effects and marketing strategies.

The unfolding narrative in this collection delves into the complexities surrounding mental health treatment and the pharmaceutical industry, highlighting the struggles faced by patients and advocates. The authors, drawing from their diverse backgrounds, provide a powerful examination of how corporate interests can overshadow the well-being of individuals, urging readers to critically assess the implications of such practices on society at large.